| __timestamp | Eli Lilly and Company | Merck & Co., Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4932500000 | 16768000000 |
| Thursday, January 1, 2015 | 5037200000 | 14934000000 |
| Friday, January 1, 2016 | 5654900000 | 13891000000 |
| Sunday, January 1, 2017 | 6070200000 | 12775000000 |
| Monday, January 1, 2018 | 4681700000 | 13509000000 |
| Tuesday, January 1, 2019 | 4721200000 | 14112000000 |
| Wednesday, January 1, 2020 | 5483300000 | 13618000000 |
| Friday, January 1, 2021 | 7312800000 | 13626000000 |
| Saturday, January 1, 2022 | 6629800000 | 17411000000 |
| Sunday, January 1, 2023 | 7082200000 | 16126000000 |
Unleashing insights
In the competitive landscape of the pharmaceutical industry, Eli Lilly and Company and Merck & Co., Inc. have long been titans. Over the past decade, from 2014 to 2023, these companies have shown distinct trends in their cost of revenue, a critical metric reflecting the direct costs attributable to the production of goods sold by a company.
Eli Lilly's cost of revenue has seen a steady increase, rising approximately 44% from 2014 to 2023. Notably, 2021 marked a peak with a 48% increase compared to 2014, indicating strategic investments in production capabilities. In contrast, Merck's cost of revenue has fluctuated, peaking in 2022 with a 4% increase from 2014, but generally maintaining a higher baseline than Eli Lilly.
These trends highlight the differing strategies of these pharmaceutical giants, with Eli Lilly focusing on scaling production and Merck maintaining a robust, consistent output.
Eli Lilly and Company vs Regeneron Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Eli Lilly and Company vs Johnson & Johnson
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Merck & Co., Inc.
Cost of Revenue Comparison: Eli Lilly and Company vs Biogen Inc.
Comparing Cost of Revenue Efficiency: Eli Lilly and Company vs Viatris Inc.
Cost Insights: Breaking Down Eli Lilly and Company and Telix Pharmaceuticals Limited's Expenses
Cost Insights: Breaking Down Eli Lilly and Company and Geron Corporation's Expenses
Merck & Co., Inc. vs Zoetis Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Merck & Co., Inc. and Intra-Cellular Therapies, Inc.
Analyzing Cost of Revenue: Merck & Co., Inc. and Corcept Therapeutics Incorporated
Comparing Cost of Revenue Efficiency: Merck & Co., Inc. vs Ionis Pharmaceuticals, Inc.
Cost of Revenue Comparison: Merck & Co., Inc. vs MorphoSys AG